Asymptomatic HIV infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Asymptomatic HIV infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of Dasatinib in Patients with Recent HIV-1 Infection https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-dasatinib-in-patients-with-recent-hiv-1-infection/ Wed, 29 Apr 2026 15:02:34 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-dasatinib-in-patients-with-recent-hiv-1-infection/ This clinical trial is focused on studying the safety and tolerance of a medication called dasatinib in patients who have recently been infected with HIV-1 but do not show any symptoms. Dasatinib is a type of medication known as a protein kinase inhibitor, which means it works by blocking certain proteins that help the virus grow. The study will compare the effects of dasatinib with a placebo, which is a substance that looks like the medication but does not contain any active ingredients.

The purpose of the study is to evaluate how safe and tolerable dasatinib is for people with recent HIV-1 infection. Participants will take the medication for a period of time, and researchers will monitor them to see how their bodies respond. The study will also look at how the medication affects the immune system and the levels of the virus in the body. This includes checking the number of certain immune cells and markers of inflammation, as well as measuring the amount of virus present before starting any other antiretroviral therapy.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how dasatinib impacts the virus and the immune system. The study aims to provide valuable insights into whether dasatinib can be a safe and effective treatment option for people with recent HIV-1 infection. The trial is expected to continue until 2026, allowing researchers to collect comprehensive data over time.

]]>